Drug­mak­ers sub­mit coun­terof­fers as part of first round of drug price ne­go­ti­a­tions

The Biden Ad­min­is­tra­tion on Mon­day con­tin­ued to tout its ef­forts to low­er drug prices, not­ing in a state­ment ahead of a like­ly drug-pric­ing-heavy State of the Union on Thurs­day that man­u­fac­tur­ers for all 10 drugs se­lect­ed for ne­go­ti­a­tions have sub­mit­ted coun­terof­fers to CMS.

The ad­min­is­tra­tion is fight­ing ef­forts to over­turn the drug pric­ing pro­vi­sions from the In­fla­tion Re­duc­tion Act in court — As­traZeneca lost a key case on Fri­day — as well as in Con­gress. Last Au­gust, CMS un­veiled the first 10 drugs that will be sub­ject to price ne­go­ti­a­tions un­der the IRA, in­clud­ing sev­er­al that may face com­pe­ti­tion from gener­ics be­fore the ne­go­ti­at­ed prices take ef­fect in 2026.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.